Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB trimmed its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 29.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 839,131 shares of the biopharmaceutical company’s stock after selling 350,869 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Dynavax Technologies were worth $10,716,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of DVAX. Smartleaf Asset Management LLC lifted its stake in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 2,034 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Dynavax Technologies in the fourth quarter worth approximately $71,000. Nisa Investment Advisors LLC increased its position in shares of Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 1,076 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in Dynavax Technologies in the 3rd quarter valued at $89,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th.

Dynavax Technologies Stock Down 1.6 %

NASDAQ DVAX opened at $12.65 on Friday. The business’s fifty day simple moving average is $13.37 and its 200-day simple moving average is $12.55. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm has a market cap of $1.57 billion, a PE ratio of 70.28 and a beta of 1.23. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. As a group, equities analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.